Literature DB >> 1696937

Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody.

L Blanco1, E M Choi, K Connolly, M R Thompson, P F Bonventre.   

Abstract

Toxic shock syndrome toxin 1 (TSST-1), a 22-kilodalton protein made by strains of Staphylococcus aureus harboring the chromosomal toxin gene, may elicit toxic shock syndrome in humans. In vitro, TSST-1 induces T cells to proliferate and macrophages to secrete interleukin-1. To conduct a structure-function analysis, point mutations on the TSST-1 gene were generated by site-directed mutagenesis to identify amino acids critical for activity of the toxin. Specific tyrosine and histidine residues were replaced by alanines. Wild-type and mutant TSST-1 gene constructs were expressed in Escherichia coli, and the products were tested for their mitogenic potential and reactivity with a TSST-1 neutralizing monoclonal antibody (MAb 8-5-7). Four of the mutants were similar to the wild type; i.e., the mutant toxins stimulated murine T cells and reacted with MAb 8-5-7 equally as well as the wild type. Two mutants exhibited a decrease in mitogenic activity, but one of these retained the capacity to bind with MAb 8-5-7 while the other was no longer recognized by the same antibody. One double mutant demonstrated minimal mitogenic activity and did not react in enzyme-linked immunosorbent and immunoblot assays with MAb 8-5-7. The data show that specific residues near the carboxy terminus of TSST-1 are essential for mitogenic activity and in forming the epitope recognized by neutralizing MAb 8-5-7.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696937      PMCID: PMC313605          DOI: 10.1128/iai.58.9.3020-3028.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Identification of functional antigenic segments of toxic shock syndrome toxin 1 by differential immunoreactivity and by differential mitogenic responses of human peripheral blood mononuclear cells, using active toxin fragments.

Authors:  C Edwin; E H Kass
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

3.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose.

Authors:  J Kyhse-Andersen
Journal:  J Biochem Biophys Methods       Date:  1984-12

4.  Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated toxin fragments.

Authors:  D A Blomster-Hautamaa; R P Novick; P M Schlievert
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

5.  Toxic-shock-syndrome toxin 1-induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes.

Authors:  N J Poindexter; P M Schlievert
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

6.  Induction of human interleukin-1 by toxic-shock-syndrome toxin-1.

Authors:  J Parsonnet; R K Hickman; D D Eardley; G B Pier
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

7.  Analysis of the mitogenic effects of toxic shock toxin on human peripheral blood mononuclear cells in vitro.

Authors:  S E Calvano; F W Quimby; A C Antonacci; R F Reiser; M S Bergdoll; P Dineen
Journal:  Clin Immunol Immunopathol       Date:  1984-10

8.  Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo.

Authors:  P F Bonventre; M R Thompson; L E Adinolfi; Z A Gillis; J Parsonnet
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

9.  Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers.

Authors:  P F Bonventre; C Linnemann; L S Weckbach; J L Staneck; C R Buncher; E Vigdorth; H Ritz; D Archer; B Smith
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

10.  A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1.

Authors:  J Parsonnet; Z A Gillis; A G Richter; G B Pier
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

View more
  18 in total

Review 1.  Exotoxins of Staphylococcus aureus.

Authors:  M M Dinges; P M Orwin; P M Schlievert
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Application of a Chimeric Protein Construct having Enterotoxin B and Toxic Shock Syndrome Toxin Domains of S. aureus in Immunodiagnostics.

Authors:  R Shylaja; Devi Kalyan Kumar Thakasi; H S Murali; K Prakash Narayana Reddy; H V Batra
Journal:  Indian J Microbiol       Date:  2012-03-31       Impact factor: 2.461

3.  Mutational analysis of superantigen activity responsible for the induction of skin erythema by streptococcal pyrogenic exotoxin C.

Authors:  J Yamaoka; E Nakamura; Y Takeda; S Imamura; N Minato
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

4.  The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental Staphylococcus aureus arthritis.

Authors:  M Verdrengh; W Kum; A Chow; A Tarkowski
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

5.  Localization of biologically important regions on toxic shock syndrome toxin 1.

Authors:  D L Murray; C A Earhart; D T Mitchell; D H Ohlendorf; R P Novick; P M Schlievert
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

6.  Predictions of T-cell receptor- and major histocompatibility complex-binding sites on staphylococcal enterotoxin C1.

Authors:  M L Hoffmann; L M Jablonski; K K Crum; S P Hackett; Y I Chi; C V Stauffacher; D L Stevens; G A Bohach
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.

Authors:  M Dohlsten; G Hedlund; E Akerblom; P A Lando; T Kalland
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Authors:  B G Stiles; T Krakauer; P F Bonventre
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome.

Authors:  P F Bonventre; H Heeg; C Cullen; C J Lian
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation.

Authors:  C M Cullen; L R Blanco; P F Bonventre; E Choi
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.